Enrolling by invitationNCT07050160
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Studying Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lexeo Therapeutics
- Principal Investigator
- Lexeo Clinical TrialsLexeo Therapeutics
- Enrollment
- 10 enrolled
- Eligibility
- 18-67 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07050160 on ClinicalTrials.govOther trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06174220Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyHamilton Health Sciences Corporation
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06109181Gene Therapy for ACM Due to a PKP2 Pathogenic VariantLexeo Therapeutics
See all trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant →